Resolution of the Advisory Board "Issues of updating Russian clinical guidelines for the diagnosis and treatment of ankylosing spondylitis and psoriatic arthritis"

1. Erdes Sh, Badokin VV, Bochkova AG, Bugrova OV, Gaidukova IZ, Godzenko AA, et al. On the terminology of spondyloarthritis. Nauchcno-Practicheskaya Revmatologia = Rheumatology Science and Practice. 2015;53(6):657-660 (In Russ.). doi: 10.14412/1995-4484-2015-657-660

2. Kotsis K, Voulgari PV, Drosos AA, Carvalho AF, Hyphantis T. Health-related quality of life in patients with ankylosing spondylitis: A comprehensive review. Expert Rev Pharmacoecon Outcomes Res. 2014;14(6):857-872. doi: 10.1586/14737167.2014.957679

3. Zochling J, Braun J. Mortality in ankylosing spondylitis. Clin Exp Rheumatol. 2008;26(5 Suppl 51):S80-S84.

4. Rudwaleit M. New approaches to diagnosis and classification of axial and peripheral spondyloarthritis. Curr Opin Rheumatol. 2010;22(4):375-380. doi: 10.1097/BOR.0b013e32833ac5cc

5. Ankylosing spondylitis: clinical guidelines. 2018. URL: http://cr.rosminzdrav.ru/#!/schema/175 (Дата доступа: 14.02.2021).

6. Lila AM, Dreval RO, Shipitsyn VV. Assessment of organization of medical care and drug provision for patients with rheumatic diseases, and the socioeconomic burden of these diseases in the Russian Federation. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2018;12(3):112-119 (In Russ.). doi: 10.14412/1996-7012-2018-3-112-119

7. Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A. Ankylosing spondylitis: An overview. Ann Rheum Dis. 2002;61(Suppl III):iii8-iii18.

8. Korotaeva TV, Korsakova YuL, Loginova EYu, Gubar EE, Chamurlieva MN. Psoriatic arthritis. Clinical guidelines for diagnosis and treatment. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2018;12(2):22-35 (In Russ.). doi: 10.14412/1996-7012-2018-2-22-35

9. Kavanaugh A, Helliwell P, Ritchlin CT. Psoriatic arthritis and burden of disease: Patient perspectives from the population-based Multinational Assessment of Psoriasis and Psoriatic arthritis (MAPP) survey. Rheumatol Ther. 2016;3:91-102. doi: 10.1007/s40744-016-0029-z

10. Coates LC, Orbai AM, Azevedo VF, Cappelleri JC, Steinberg K, Lippe R, et al. Impact of psoriatic arthritis from the patient’s perspective in the context of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire: An online global survey. Arthritis Rheumatol. 2018;70(Suppl 10). URL: https://acrabstracts.org/abstract/impact-of-psoriatic-arthritis-from-the-patients-perspective-in-the-context-of-the-psoriatic-arthritis-impact-of-diseasepsaid-questionnaire-an-online-global-survey/ (Accessed: 15th February 2021).

11. Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am. 2015;41(4):545-568. doi: 10.1016/j.rdc.2015.07.001

12. Haddad A, Zisman D. Comorbidities in patients with psoriatic arthritis. Rambam Maimonides Med J. 2017;8(1):e0004. doi: 10.5041/RMMJ.10279

13. Husted JA, Thavaneswaran A, Chandran V, Gladman DD. Incremental effects of comorbidity on quality of life in patients with psoriatic arthritis. J Rheumatol. 2013;40(8):1349-1356. doi: 10.3899/jrheum.121500.

14. Walsh JA, Adejoro O, Chastek B, Palmer JB, Hur P. Treatment patterns among patients with psoriatic arthritis treated with a biologic in the United States: Descriptive analyses from an administrative claims database. J Manag Care Spec Pharm. 2018;24(7):623-631. doi: 10.18553/jmcp.2018.24.7.623

15. Coates LC, Helliwell PS. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res (Hoboken). 2010;62(7):965-969. doi: 10.1002/acr.20155

16. Aaltonen K, Heinonen A, Joensuu J, Parmanne P, Karjalainen A, Varjolahti-Lehtinen T, Effectiveness and drug survival of TNFinhibitors in the treatment of psoriatic arthritis: A prospective cohort study. Semin Arthritis Rheum. 2017;46(6):732-739. doi: 10.1016/j.semarthrit.2016.09.005

17. Lubrano E, Perrotta FM, Scriffignano S, Coates LC, Helliwell P. Sustained very low disease activity and remission in psoriatic arthritis patients. Rheumatol Ther. 2019;6:521-528. doi: 10.1007/s40744-019-00171-w

18. Instructions for medical use of RANVEC (In Russ.). URL: https://grls.rosminzdrav.ru/GRLS.aspx (Дата доступа: 22.02.2021).

19. van der Heijde D, Song IH, Pangan AL, Deodhar A, van den Bosch F, Maksymowych WP, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): A multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. Lancet. 2019;394(10214):21082117. doi: 10.1016/S0140-6736(19)32534-6

20. Deodhar A, van der Heijde D, Sieper J, van den Bosch F, Maksymowych W, Kim TH, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis: 1-year results from a randomized, double-blind, placebo-controlled study with open-label extension. Arthritis Rheumatol. 2020;72 (Suppl 10). URL: https://acrabstracts.org/abstract/efficacy-and-safety-of-upadacitinib-in-patients-with-active-ankylosing-spondylitis-1-yearresults-from-a-randomized-double-blind-placebo-controlledstudy-with-open-label-extension/ (Accessed: 14th February 2021).

21. Deodhar A, Baraliakos X, McInnes I, de Vlam K, Bessette L, Maniccia A, et al. Effect of upadacitinib on reducing pain in patients with active ankylosing spondylitis and inadequate response to nonsteroidal anti-inflammatory drugs. Arthritis Rheumatol. 2020;72 (Suppl 10). URL: https://acrabstracts.org/abstract/effect-of-upadacitinib-on-reducing-pain-in-patients-with-active-ankylosing-spondylitis-and-inadequate-response-to-nonsteroidal-anti-inflammatory-drugs/ (Accessed: 14th February 2021).

22. Cohen S, van Vollenhoven R, Winthrop K, Zerbini CA, Tanaka Y, Bessette L, et al. Safety profile of upadacitinib in rheumatoid arthritis: Integrated analysis from the SELECT Phase 3 clinical program. Arthritis Rheumatol. 2019;71(Suppl 10). URL: https://acrabstracts.org/abstract/safety-profile-of-upadacitinib-in-rheumatoid-arthritis-integrated-analysis-from-the-select-phase-3-clinical-program/ (Accessed: 14th February 2021).

23. Burmester G, Winthrop K, Nash P, Goupille P, Azevedo VF, Salvarani C, et al. Safety profile of upadacitinib in psoriatic arthritis: Integrated analysis from two phase 3 trials. Arthritis Rheumatol. 2020;72(Suppl 10). URL: https://acrabstracts.org/abstract/safety-profile-of-upadacitinib-in-psoriatic-arthritis-integrated-analysis-from-two-phase-3-trials/ (Accessed: 12th April 2021).

24. EMA SmPC RINVOQ. URL: https://www.ema.europa.eu/en/medicines/human/EPAR/rinvoq#product-informationsection (Accessed: 9th February 2021).

25. McInnes I, Anderson J, Magrey M, Merola J, Liu Y, Kishimoto M, et al. Efficacy and safety of upadacitinib versus placebo and adalimumab in patients with active psoriatic arthritis and inadequate response to non-biologic disease-modifying anti-rheumatic drugs: A double-blind, randomized controlled phase 3 trial. Arthritis Rheumatol. 2020;72(Suppl 10). URL: https://acrabstracts.org/abstract/efficacy-and-safety-of-upadacitinib-versus-placebo-and-adalimumab-in-patients-with-active-psoriatic-arthritis-and-inadequate-response-to-non-biologic-disease-modifying-anti-rheumatic-drugs-a-double-b/ (Accessed: 14th February 2021).